Effects of IL-17A on the occurrence of lung adenocarcinoma

Cancer Biology and Therapy

Volumn 12, Issue 7, 2011, Pages 610-616

  Li, Ying ^a   Cao, Zhen Yuan ^a   Sun, Bo ^a   Wang, Guang You ^a   Fu, Zheng ^a   Liu, Yu Mei ^a   Kong, Qing Fei ^a   Wang, Jing Hua ^a   Zhang, Yao ^a   Xu, Xiang Ying ^a,b   Li, Hu Lun ^a,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c XIAMEN UNIVERSITY   (China)

Author keywords

Angiogenesis; Interleukin 17 (IL 17); Lung adenocarcinoma; Vascular endothelial growth factor (VEGF)

Indexed keywords

INTERLEUKIN 17; VASCULOTROPIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MALE; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD4; ANTIGENS, CD8; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERLEUKIN-17; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN-17; REFERENCE VALUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053396910     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.7.16302     Document Type: Article

References (26)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
2. McDougall SR, Anderson AR, Chaplain MA. Mathematical modelling of dynamic adaptive tumourinduced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol 2006; 241:564-89. (Pubitemid 44041121)
3. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev 2003; 3:401-10. (Pubitemid 37328844)
4. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Can Res 1998; 58:1408-16. (Pubitemid 28193601)
5. Rafii S, Heissig B, Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 2002; 9:631-41. (Pubitemid 34567493)
6. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Patho 1995; 146:1029-39.
7. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148:32-46. (Pubitemid 46365005)
8. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008; 10:95.
9. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620-7. (Pubitemid 36857622)
10. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112:362-73.
11. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31:787-98.
12. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008; 374:533-7.
13. + T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009; 125:1372-9.
14. + T-cell axis in patients with breast cancer. Br J Cancer 2009; 100:1061-7.
15. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration downregulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 2009; 66:169-75.
16. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15:114-23.
17. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175:6177-89. (Pubitemid 41508106)
18. Maniati E, Soper R, Hagemann T. Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29:5653-62.
19. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073-81.
20. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307.
21. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66:8887-96. (Pubitemid 44449207)
22. Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood 2008; 112:4940-7.
23. Nilsson G. Effect of bulbar acidification on basal secretion of acid and gastrin in dog. Acta physiologica Scandinavica 1975; 95:477-81.
24. Suidan GL, McDole JR, Chen Y, Pirko I, Johnson AJ. Induction of blood brain barrier tight junction protein alterations by CD8 T cells. PloS one 2008; 3:3037.
25. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab Invest 1992; 67:519-28.
26. Griffith CK, Miller C, Sainson RC, Calvert JW, Jeon NL, Hughes CC, et al. Diffusion limits of an in vitro thick prevascularized tissue. Tissue Eng 2005; 11:257-66. (Pubitemid 40515193)